Online citations, reference lists, and bibliographies.
← Back to Search

Nab-paclitaxel In The Treatment Of Metastatic Breast Cancer: A Comprehensive Review

A. Montero, B. Adams, C. Diaz-Montero, Stefan Glück
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The novel paclitaxel formulation (nanoparticle albumin-bound [nab] paclitaxel (Abraxane®) has recently been approved by the US FDA for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months after adjuvant chemotherapy. Apart from its superior efficacy, as demonstrated in the pivotal Phase III study, less toxicity compared with the traditional solvent-containing paclitaxel (Taxol®) seems to contribute to its favorable therapeutic index. While approved as a single agent, nab-paclitaxel may prove more effective in combination with either biologic agents and/or other cytotoxic chemotherapeutic agents, as summarized in this article.
This paper references
10.1200/JCO.2005.02.027
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
S. Jones (2005)
10.3816/CBC.2007.n.049
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Joanne L. Blum (2007)
10.2147/TCRM.S3120
Gemcitabine and taxanes in metastatic breast cancer: a systematic review
Vinay Gudena (2008)
10.1097/JTO.0b013e31816de2a7
Phase I Trial of Nanoparticle Albumin-Bound Paclitaxel in Combination with Gemcitabine in Patients with Thoracic Malignancies
T. Stinchcombe (2008)
10.3322/canjclin.39.6.399
Cancer statistics
N. Dubrawsky (1989)
10.3322/caac.20006
Cancer Statistics, 2009
A. Jemal (2009)
10.1200/JCO.2004.00.6148
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
D. Nyman (2005)
10.1093/jnci/djp235
International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy
F. Cardoso (2009)
10.3816/CBC.2005.N.042
North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer.
A. Moreno-Aspitia (2005)
10.1093/annonc/mdn661
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
V. Roy (2009)
Los Angeles, CA, USA
J. Cohen (2002)
10.1158/1078-0432.CCR-05-1634
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
N. Desai (2006)
[A tolerability study of A cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor].
Xiao-yu Teng (2004)
Albuminbound paclitaxel: in metastatic breast cancer
DM Robinson (2006)
10.1038/sj.bjc.6602680
A systematic review of taxane-containing regimens for metastatic breast cancer
D. Ghersi (2005)
Bristol-Myers Squibb Company
® Taxol
10.1200/JCO.2007.10.8399
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
M. Piccart-Gebhart (2008)
10.2165/00003495-200666070-00007
Albumin-Bound Paclitaxel
D. Robinson (2012)
10.1093/JNCI/83.4.288
Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.
I. Ringel (1991)
Abraxane) in combination with gemcitabine in patients with metastatic breast cancer
(2005)
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
N. Ibrahim (2002)
10.1200/JCO.2005.04.937
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
W. Gradishar (2005)
10.1200/JCO.2008.18.5397
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
W. Gradishar (2009)
Measurement of fraction unbound paclitaxel in human plasma.
E. Brouwer (2000)
10.1016/J.BIOPHA.2007.08.008
Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute.
C. Lobo (2007)
10.1200/JCO.2007.11.6699
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
A. Seidman (2008)
Albumin-bound nanoparticle paclitaxel.
W. Gradishar (2005)
10.1007/s10549-010-1002-0
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
C. Lobo (2010)
10.1093/ANNONC/MDI904
Chemotherapy for metastatic breast cancer.
S. Barni (2005)
10.1056/NEJMoa0707056
Weekly paclitaxel in the adjuvant treatment of breast cancer.
J. Sparano (2008)
10.1200/JCO.2007.11.9362
Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.
K. Albain (2008)
10.1016/S0959-8049(01)00171-X
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
H. Gelderblom (2001)
10.1200/JCO.2005.11.013
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.
N. Ibrahim (2005)



This paper is referenced by
10.1186/1477-3155-11-S1-S6
Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice
S. Valetti (2013)
10.1007/978-3-030-29168-6_2
Breast Cancer Receptors and Targeting Strategies
Ashish Pandit (2019)
10.1515/ejnm-2014-0026
Albendazole loaded albumin nanoparticles for ovarian cancer therapy
Lubna Noorani (2014)
10.1016/j.urology.2017.01.018
Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.
Dennis J. Robins (2017)
10.1002/ANGE.201403036
Maßgeschneiderte Nanopartikel für den Wirkstofftransport in der Krebstherapie
Tianmeng Sun (2014)
10.3390/molecules180911537
Analysis of Biotinylated Generation 4 Poly(amidoamine) (PAMAM) Dendrimer Distribution in the Rat Brain and Toxicity in a Cellular Model of the Blood-Brain Barrier
R. Hemmer (2013)
10.2174/1389200219666180918111528
Cancer Nanotechnology: A New Revolution for Cancer Diagnosis and Therapy.
V. Chaturvedi (2018)
10.1038/s41392-017-0004-3
Controlled drug delivery vehicles for cancer treatment and their performance
S. Senapati (2018)
10.7150/ijbs.9969
Decrease of Let-7f in Low-Dose Metronomic Paclitaxel Chemotherapy Contributed to Upregulation of Thrombospondin-1 in Breast Cancer
Weiyang Tao (2015)
10.1002/jbm.b.33564
In vitro and in vivo evaluation of effect of excipients in local delivery of paclitaxel using microporous infusion balloon catheters.
Jordan A. Anderson (2017)
10.1007/S12094-013-1095-0
SEOM clinical guidelines for the management of metastatic breast cancer 2013.
A. Cussac (2013)
10.1186/s12885-015-2027-x
The treatment patterns, efficacy, and safety of nab®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis
Caihua Liang (2015)
10.5430/JST.V3N1P21
Eribulin monotherapy in a patient with heavily pretreated metastatic breast cancer: Case study and review of the literature
Fariborz Gorouhi (2012)
10.1186/s12951-016-0193-x
Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy
Ewelina Piktel (2016)
10.1016/J.JDDST.2019.101168
Disulfide-crosslinked reduction-responsive Prodrug Micelles for On-demand Paclitaxel Release
Zhonghang Wang (2019)
10.1039/c5nr07853a
Recent advances in multifunctional silica-based hybrid nanocarriers for bioimaging and cancer therapy.
Wei Qi Lim (2016)
10.1021/acs.molpharmaceut.8b00527
Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles.
Faquan Li (2018)
10.1016/j.biotechadv.2015.10.002
Development of nanotheranostics against metastatic breast cancer--A focus on the biology & mechanistic approaches.
A. Subramanian (2015)
Development and application of flow experiments for quantitative studies on nanoparticle binding to biological surfaces
Ellen Broda (2016)
10.1039/C4RA16346J
Self-assembled serum albumin–poly(L-lactic acid) nanoparticles: a novel nanoparticle platform for drug delivery in cancer
Lin Dai (2015)
Inorganic Compounds Going NANO
Alexandra R. Fernandess (2015)
In contrast to solvent-based taxane regimens, nab-paclitaxel does not require steroid premedication, and may be an option for patients who exhibit hypersensitivity to solvent-based taxane preparations. Practice Points Taxane chemotherapy treatment for metastatic breast cancer MANAGEMENT PERSPECTIVE
Della F. Makower (2013)
10.1158/1535-7163.MCT-14-0357
Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma
R. Gowda (2014)
10.4161/cam.20210
The mesenchymal tumor microenvironment
E. Cukierman (2012)
10.1016/j.actbio.2017.03.009
Multi-stimuli-responsive biohybrid nanoparticles with cross-linked albumin coronae self-assembled by a polymer-protein biodynamer.
L. Wang (2017)
Annals of Medicinal Chemistry and Research
Carolina Mota (2015)
10.1039/c8fo00446c
Melissa officinalis L. ethanolic extract inhibits the growth of a lung cancer cell line by interfering with the cell cycle and inducing apoptosis.
D. B. Magalhães (2018)
10.1016/J.COSSMS.2012.10.004
Nanocrystals for the parenteral delivery of poorly water-soluble drugs.
B. Sun (2012)
10.2147/IJN.S93835
An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line
Xinzhe Yu (2015)
10.1007/s12609-011-0066-0
Novel Cytotoxic Agents in the Treatment of Metastatic Breast Cancer
Sean Warsch (2012)
10.1016/bs.apcsb.2014.12.003
Hybrid protein-synthetic polymer nanoparticles for drug delivery.
N. Koseva (2015)
10.1002/mabi.201600131
Enhanced Targeted Delivery of Cyclodextrin-Based Supermolecules by Core-Shell Nanocapsules for Magnetothermal Chemotherapy.
I. Lin (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar